Table 1 CLEAR I and CLEAR II RA patient characteristics at the time of enrollment in the registries and stratification by anti-PAD4 and anti-PAD4/PAD3 positivity
All patients | Anti-PAD4-negative (P0) | Anti-PAD4 only (P4) | Anti-PAD4/PAD3 (XR) | P value | |||
|---|---|---|---|---|---|---|---|
Demographic and RA-related variable | (N = 192) | (N = 146) | (N = 26) | (N = 20) | P4 vs P0 | XR vs P0 | XR vs P4 |
Age (years), mean (SD) | 55 (12.2) | 54 (12.1) | 55 (13.9) | 59 (8.6) | 0.755 | 0.077 | 0.288 |
Female, % | 86 | 85 | 96 | 80 | 0.207 | 0.523 | 0.151 |
Disease duration (years), mean (SD) | 8.1 (10.8) | 7.2 (10.5) | 10.4 (11.2) | 12.8 (11.6) | 0.029 | 0.004 | 0.386 |
+anti-CCP, % | 73 | 67 | 88 | 95 | 0.035 | 0.008 | 0.622 |
Total radiographic score,a median (IQR) | 2 (0–57) | 2 (0–11) | 2 (1–104) | 76 (3–117) | 0.231 | 0.001 | 0.082 |
CRP (mg/dl) | 14 (36) | 16 (40) | 8 (10) | 9 (13) | 1.000 | 0.391 | 0.598 |
Smoking, % | 0.387 | 0.183 | 0.852 | ||||
Current | 56 | 33 | 19 | 15 | |||
Former | 45 | 21 | 27 | 35 | |||
Never | 92 | 46 | 54 | 50 | |||
Medications, % | |||||||
Methotrexate | 63 | 63 | 69 | 85 | 0.660 | 0.080 | 0.302 |
HCQ | 29 | 29 | 34 | 20 | 0.645 | 0.441 | 0.336 |
Sulfasalazine | 8 | 8 | 8 | 5 | 1.000 | 1.000 | 1.000 |
Leflunomide | 5 | 5 | 0 | 5 | 0.600 | 1.000 | 0.435 |
Infliximab | 4 | 4 | 0 | 10 | 0.593 | 0.248 | 0.184 |
Etanercept | 4 | 4 | 4 | 10 | 1.000 | 0.248 | 0.572 |